Go Pro

Extendicare Inc. (TSE:EXE) Receives Consensus Rating of "Buy" from Brokerages

Extendicare logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is positive: Extendicare has a consensus “Buy” rating from eight analysts, with an average 12-month price target of C$37.00.
  • Recent financial results were solid: The company reported quarterly revenue of C$611.04 million and earnings of C$0.32 per share, alongside a 6.13% net margin and 36.33% return on equity.
  • Extendicare continues to pay a monthly dividend: Its latest dividend was C$0.0441 per share, representing an annualized yield of approximately 1.7% and a payout ratio of 39.23%.
  • Five stocks to consider instead of Extendicare.

Extendicare Inc. (TSE:EXE - Get Free Report) has earned a consensus recommendation of "Buy" from the eight analysts that are currently covering the stock, Marketbeat reports. Seven analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is C$37.00.

Several equities research analysts have weighed in on the company. Desjardins reduced their price objective on Extendicare from C$40.00 to C$39.00 and set a "buy" rating on the stock in a research note on Monday, August 10th. Canaccord Genuity Group lifted their target price on Extendicare from C$37.00 to C$44.00 and gave the stock a "buy" rating in a report on Monday, August 10th. Royal Bank Of Canada boosted their target price on Extendicare from C$38.00 to C$39.00 and gave the company an "outperform" rating in a research report on Friday, August 14th. Finally, National Bank Financial increased their price target on Extendicare from C$34.00 to C$40.00 and gave the company an "outperform" rating in a report on Wednesday, May 27th.

Read Our Latest Stock Report on Extendicare

Extendicare Stock Performance

Shares of TSE:EXE opened at C$30.45 on Friday. Extendicare has a 52 week low of C$13.30 and a 52 week high of C$39.14. The stock has a market capitalization of C$2.89 billion, a P/E ratio of 23.32 and a beta of 1.36. The firm has a fifty day simple moving average of C$33.36 and a two-hundred day simple moving average of C$31.70. The company has a quick ratio of 0.98, a current ratio of 0.75 and a debt-to-equity ratio of 159.54.

Extendicare (TSE:EXE - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported C$0.32 earnings per share (EPS) for the quarter. Extendicare had a net margin of 6.13% and a return on equity of 36.33%. The firm had revenue of C$611.04 million for the quarter. On average, analysts expect that Extendicare will post 0.6134729 earnings per share for the current fiscal year.

Extendicare Dividend Announcement

The company also recently disclosed a monthly dividend, which was paid on Monday, August 17th. Shareholders of record on Monday, August 17th were given a dividend of $0.0441 per share. The ex-dividend date was Friday, July 31st. This represents a c) dividend on an annualized basis and a yield of 1.7%. Extendicare's payout ratio is 39.23%.

Extendicare Company Profile

(Get Free Report)

Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services.

Further Reading

Analyst Recommendations for Extendicare (TSE:EXE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Extendicare Right Now?

Before you consider Extendicare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Extendicare wasn't on the list.

While Extendicare currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines